Pusat sent abroad by Polat Alemdar, Cypress and Nesrin Cakir, published this week in the Valley of the Wolves Pusu'nun back to Turkey! kurtlar vadisi pusu izle Cakir caused his family brought from abroad, what will happen? Pusat eagerly waiting for all of Turkey, what to do? Polat Alemdar and to live the question of what Lil Wayne Ulubey Pusu'nun encounter a whole new section will answer ... The time now wolves

Audiences with an enthralling scenario Ezel sequence typing and Kenan Birkanla yapıt.Özellikle Ramis Karaeski increases a little more excitement of the battle array. Show able to watch TV channels on Monday evenings Ezel sequence.
Also enjoyed the array array of those who missed the link below to watch the Ezel
ezel son bölüm izle

The Next Post Blogging To The Next Level

The results of a paper published in the journal Chest (129(5):1219-25) show that alcoholic and ex-alcoholic individuals have a higher risk of suffering from community acquired pneumonia.

Although mortality did not differ significantly, an increase of the severeness of the disease was shown, and consequently, an increase of the morbidity and the complications was revealed. This study was conducted by the Pneumonia Multidiscipline Group of Hospital Clínic de Barcelona, led by Dr. Antoni Torres, from the Institut Clínic del Tórax, and leader of the IDIBAPS Group Management and Prevention of the Pulmonary Disease.

The increase of the risk of suffering from pneumonia in alcoholic patients exists due to the fact that the activity of their immune system decreases. This decrease not only is observed in alcoholic, but also in ex alcoholic patients. The daily quantity of alcohol consumption in order to include patients in the group of alcohol abuse was of 80 g in man and 60 g in women, the equivalent of 2 or 3 beers and 3 or 4 cups of wine.

Results are especially relevant since alcohol is the more abused drug in Spain, and causes a total of 12,000 deaths every year. In addition, pneumonia is a very frequent disease, with 10 patients every 1,000 inhabitants in Catalonia. This number is much higher if we take into account in the population over 65. This is the reason why the consequences of this study, and the possible vaccination of alcoholic of ex-alcoholic individuals against Pneumococcus, would affect a very high number of people. Alcohol consumption could turn into a new risk factor or a worsening factor to take into account in cases of community acquired pneumonia.

Until now, women had to rely on prevention and treatment guidelines for coronary heart disease based on research on men.

This month, the American Heart Association outlined measures for women to combat and prevent cardiovascular disease, the first evidence-based guidelines for women.

Coronary heart disease (CHD) is often fatal, and because nearly two thirds of women who die suddenly have no previously recognized symptoms, it is thus essential to prevent CHD. AHA figures show that about half a million women die of heart disease and strokes each year, killing more than the next seven causes of death combined, including cancer.

In comparisons between the genders, WomenHeart, the National Coalition for Women with Heart Disease, says that women are more likely than men to die within one year of a heart attack; women are twice as likely as men to die after a bypass; and 35 percent of female and 18 percent of male heart attack survivors will have a recurrent heart attack within six years.

Risk factors for cardiovascular disease in both men and women include high cholesterol and blood pressure, smoking, not exercising, obesity, stress and a family history of heart disease and stroke.

A small-molecule drug may be capable of preventing arrhythmias according to a team of researchers at Columbia University Medical Center. The new drug called JTV519 has been developed and tested in mice. It targets leaky calcium channels. Heart arrhythmias, which are characterized by fast and erratic beating of the heart, can cause sudden death. This is particularly more common in people with heart failure or otherwise weakened hearts.
The Role of Calcium Channels

In the normal heart cell, the membrane surrounding a heart cell contains a small calcium channel that is stimulated by the electrical impulses that drive heart rhythm. When stimulated, this calcium channel triggers another, larger calcium channel within the cell, called the ryanodine receptor (RyR2), to release calcium ions. The rush of calcium ions then signals the heart muscle to contract powerfully. The ryanodine receptor sits at the surface of the sarcoplasmic reticulum, a sac containing calcium ions, and is the major gatekeeper for calcium ion release. The more calcium released through the ryanodine receptor, the stronger the contraction of the heart.

In a previous study, the same research team found that the calcium channels from patients with heart failure have defective function that, in addition to making them unresponsive to further stimulation by catecholamines, also causes a calcium leak that can weaken heart muscle contraction and possibly trigger fatal heart arrhythmias. These arrhythmias, known as ventricular fibrillation, are the cause of death in about 50 percent of patients with heart failure.

RyR2, is normally held closed by the interaction of another protein called calstabin2. When calstabin binds it, the channel does not open, and no calcium is released. But when the interaction of RyR2 and calstabin2 is disrupted, the channel begins to leak Ca2+, triggering arrhythmia.

Study details

The research, led by Andrew Marks, MD, Director of the Center for Molecular Cardiology at Columbia University Medical Center, was set to investigate whether a drug known to enhance calstabin2 - ryanodine receptor binding could prevent the development of arrhythmias.

The experimental drug JTV519, a 1,4-benzothiazepine derivative, has recently been shown to reduce diastolic sarcoplasmic reticulum Ca2 leak in an animal model of heart failure. JTV519 was shown to increase binding of the protein calstabin2 to the ryanodine receptor hence the potential for blocking arrhythmias.

The study was conducted using mice which either had defective calstabin2 or had no calstabin2. Some of the mice were given the experimental drug. Both groups were then exercised to induce arrhythmias. The 10 mice that received the drug did not develop an arrhythmia, whereas 8 of 9 untreated mice died after arrhythmic events. The experimental drug had no effect on knockout animals that had no calstabin2 suggesting that calstabin2 presence is essential for drug to function. The drug blocked potentially fatal arrhythmias in these mice by stabilizing the crucial protein-protein interaction between RyR2 and calstabin and preventing Ca2+ leakage, Marks� team reports.

References

Xander H. T. Wehrens, Stephan E. Lehnart, Steven R. Reiken, Shi-Xian Deng, John A. Vest, Daniel Cervantes,3 James Coromilas,3 Donald W. Landry, Andrew R. Marks. Protection from Cardiac Arrhythmia Through Ryanodine Receptor�Stabilizing Protein Calstabin2. Science:304 April, 2004.

Altace was found to lower the risk of sudden cardiac death and nonfatal cardiac arrest in people at high risk of heart attacks and stroke.

Altace (Rimipril) belongs to a class of drugs known as Angiotensin-converting enzyme (ACE) inhibitors. ACE inhibitors are widely prescribed to patients following heart attacks and for those with heart failure. They are also recommended for people with high blood pressure, diabetes, and others at risk for ACE inhibitors and stroke.

Altace blocks ACE from converting angiotensin I to angiotensin II, a powerful vasoconstrictor, leading to decreased blood pressure, decreased aldosterone secretion, a small increase in serum potassium levels, and sodium and fluid loss; increased prostaglandin synthesis also may be involved in the antihypertensive action.

Past studies have shown that these medications reduce the risk of heart attack and stroke in people with heart disease.
The HOPE Trial

The Heart Outcomes Prevention Evaluation (HOPE) study followed a total of 9,297 high-risk patients who were aged 55+ either with a history of coronary artery disease (CAD), stroke, or peripheral vascular disease (PVD) or with diabetes plus at least one other cardiovascular risk factor (hypertension, elevated total cholesterol level, low high-density lipoprotein cholesterol level, cigarette smoking, or documented microalbuminuria.

The double blind, randomized study compared Altace with vitamin E or placebo treatment. Researchers now report that after an average of 4.5 years of treatment, 3% of the patients taking the ACE inhibitor had died from sudden cardiac death or experienced a nonfatal cardiac arrest, compared with 4% taking placebo. This translates into a 21% reduction in unexpected deaths, deaths due to cardiac arrest, or nonfatal cardiac arrest for those taking Altace.

In the HOPE study, roughly three out of four patients were also taking a blood thinner, a third were taking cholesterol-lowering statins, half were taking calcium channel blockers (another type of high blood pressure medication), and two out of five were taking beta-blockers. Thus showing that even when people were on other medications, they benefited from being on an ACE inhibitor.

These results stressed the importance in prescribing ACE inhibitors to patients at high risk of developing heart disease and stroke.